What is the Market's View on Celcuity Inc (CELC) Stock's Price and Volume Trends Monday?

Overall market sentiment has been high on Celcuity Inc (CELC) stock lately. CELC receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.

Celcuity Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on CELC!

See Full CELC Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With CELC Stock Today?

Celcuity Inc (CELC) stock is trading at $21.83 as of 9:38 AM on Monday, Apr 1, a gain of $0.23, or 1.04% from the previous closing price of $21.60. The stock has traded between $21.64 and $22.04 so far today. Volume today is below average. So far 218 shares have traded compared to average volume of 279,961 shares.

More About Celcuity Inc

Celcuity Inc is clinical-stage biotechnology company seeking to extend the lives of cancer patients by pursuing an integrated therapeutic (Rx) and companion diagnostic (CDx) strategy. The company's drug candidate, gedatolisib, is a potent, well-tolerated, small molecule dual inhibitor, administered intravenously, that selectively targets all class I isoforms of PI3K and mammalian target of rapamycin (mTOR). Click Here to get the full Stock Report for Celcuity Inc stock.